Asia Fresh News

Asia Fresh Stories

Archive for April 21st, 2015

Thousands of DC Comics Fans Gather to Set Guinness World Record for Most People Dressed as DC Comics Super Heroes in a 24-Hour Period

leave a comment »

— From Australia to America, Thousands of Fans Across the Globe Set New World Record

BURBANK, Calif., April 20, 2015 /PRNewswire/ — Warner Bros. Consumer Products (WBCP) and DC Entertainment (DCE) today hosted fans around the world to set a Guinness World Record for the largest gathering of people dressed as DC Comics Super Heroes. In a 24-hour period, thousands of fans gathered around the globe to participate in the DC Comics Super Hero World Record Event by donning their favorite costumes inspired by DC Comics’ pantheon of Super Heroes, including Batman, Superman, Wonder Woman, The Flash, Green Lantern, Batgirl, Supergirl, Aquaman, Cyborg, Robin, Green Arrow and many more.

Photo – http://photos.prnewswire.com/prnh/20150419/199538
Photo – http://photos.prnewswire.com/prnh/20150419/199542
Photo – http://photos.prnewswire.com/prnh/20150419/199540

“Thanks to all the fans of DC Comics Super Heroes around the world who joined us to set a world record — a record that celebrates the power and appeal of these iconic characters,” said Brad Globe, President of Warner Bros. Consumer Products.

The DC Comics Super Hero World Record Event kicked off on April 18, 2015 in Queensland, Australia, and came to a commemorative close in Los Angeles, CA, USA. Within the same 24-hour period, additional events took place around the world in: Manila, Philippines; Kaohsiung, Taiwan; Madrid, Spain; Rome, Italy; London, Birmingham, Warrington and Cardiff in the UK; Sao Paulo, Brazil; Paris, France “Smallville,” USA (Plano, IL) and Mexico City, Mexico.

Fans are highlighting their participation in the heroic event using #DCWorldRecord on Facebook and Twitter. The official Guinness World Record count will be available in the coming days.

Complimentary B-roll and images from the global events are available for download here: https://edelmanftp.box.com/s/wmg9caponznfvz02xcfshow8kliukxom.

About Warner Bros. Consumer Products
Warner Bros. Consumer Products, a Warner Bros. Entertainment Company, is one of the leading licensing and retail merchandising organizations in the world.

About DC Entertainment
DC Entertainment, home to iconic brands DC Comics (Superman, Batman, Green Lantern, Wonder Woman, The Flash), Vertigo (Sandman, Fables) and MAD, is the creative division charged with strategically integrating its content across Warner Bros. Entertainment and Time Warner. DC Entertainment works in concert with many key Warner Bros. divisions to unleash its stories and characters across all media, including but not limited to film, television, consumer products, home entertainment and interactive games. Publishing thousands of comic books, graphic novels and magazines each year, DC Entertainment is the largest English-language publisher of comics in the world.

JUSTICE LEAGUE and all related characters and elements are trademarks of and © DC Comics.
(s15)

MEDIA CONTACTS:

Warner Bros. Consumer Products

Edelman on Behalf of WBCP

Janice Aguilar-Herrero

Emily Erskine

office: 818-954-3821 / cell: 818-383-4144

office: 323-202-1021 / cell: 818-212-3403

janice.aguilar-herrero@warnerbros.com

emily.erskine@edelman.com
Source: Warner Bros. Consumer Products

Written by asiafreshnews

April 21, 2015 at 11:58 pm

Posted in Uncategorized

Dulwich College Launches Sea Flagship Campus With up to $400 Million Investment in Singapore School Catering to Mobile Families Across Asia

leave a comment »

— Part of an international education network building momentum across Asia over the last decade, providing enhanced education with strong heritage and international perspective
— Dulwich College (Singapore) is the sixth campus in Asia and seventh in the Dulwich network, with investment of up to S$400million to develop state-of-the-art facilities on 50,000 sqm site
— 920 students enrolled to date, set to grow organically year-on-year, with an eventual capacity of 2,500

SINGAPORE  /PRNewswire/ — Dulwich College (Singapore) celebrated its grand opening on 17 April, to mark its inaugural Founder’s Day ceremony. The Singapore campus is the network’s SEA flagship, its sixth school in Asia, complementing an established network of schools across China and Korea.

Dr. Amy Khor, Senior Minister of State for Ministry of Health and Ministry of Manpower, and Dr. Joseph Spence, Master of Dulwich College in London, preparing to cut the ribbon at Dulwich College Singapore’s inaugural Founder’s Day and official opening ceremony.
Dr. Amy Khor, Senior Minister of State for Ministry of Health and Ministry of Manpower, and Dr. Joseph Spence, Master of Dulwich College in London, preparing to cut the ribbon at Dulwich College Singapore’s inaugural Founder’s Day and official opening ceremony.
(From left to right) Dr. Amy Khor, Senior Minister of State for Ministry of Health and Ministry of Manpower, and Lord Turnbull, the Chairman of the Board of Governors at Dulwich College, unveil the inaugural Founder’s Day commemorative plaque, surrounded by 1,200 terracotta tiles handmade by every student, teacher and staff member from the first intake at Dulwich College Singapore.
(From left to right) Dr. Amy Khor, Senior Minister of State for Ministry of Health and Ministry of Manpower, and Lord Turnbull, the Chairman of the Board of Governors at Dulwich College, unveil the inaugural Founder’s Day commemorative plaque, surrounded by 1,200 terracotta tiles handmade by every student, teacher and staff member from the first intake at Dulwich College Singapore.

The opening ceremony was attended by Dr. Amy Khor, Senior Minister of State for Ministry of Health and Ministry of Manpower, Lord Turnbull, Chairman of the Board of Governors at Dulwich College, Mr. Fraser White, Founder and Executive Chairman of DCI, Mr. Christian Guertler, CEO of DCI, Mr. Nick Magnus, Headmaster of Dulwich College (Singapore), Dr. Joseph Spence, Master of Dulwich College London.

The school welcomed its first intake of 884 students in August 2014 (the largest opening population of any international school) and currently caters for Toddlers (age 2) to Year 8 (age 13). There are currently 920 students enrolled, and an eventual capacity of 2,500 students from Toddlers to Year 13. Phase 2 of the College’s construction was brought forward by one year in response to demand for places at the academically selective international school and will be completed in 2016, with a total investment of up to S$400 million.

For more information, visit http://www.dulwich-singapore.sg.

For media enquiries, please contact:
Rebecca Thomas Rebecca@aka-asia.com, +65-6222-6136
Tjan Hui Min  Huimin@aka-asia.com, +65-6222-6136

Photo – http://photos.prnasia.com/prnh/20150420/8521502442a
Photo – http://photos.prnasia.com/prnh/20150420/8521502442b

Source: Dulwich College Singapore

Written by asiafreshnews

April 21, 2015 at 4:55 pm

Posted in Uncategorized

FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection

leave a comment »

PALO ALTO, Calif., /PRNewswire/ — Eiger BioPharmaceuticals, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, lonafarnib, in combination with ritonavir for treatment of hepatitis delta virus (HDV) infection. Lonafarnib is currently in Phase 2 clinical trials for this indication.

The FDA grants Fast Track status to facilitate the development of drugs intended to treat serious or life-threatening conditions and which demonstrate the potential to address unmet medical needs. Interim results of theLOnafarnib With Ritonavir (LOWR – 1 and LOWR – 2) studies will be presented publicly for the first time this week at the European Association for the Study of the Liver (EASL) meeting in Vienna, Austria.

“We are very pleased to receive Fast Track designation for lonafarnib to address a serious unmet medical need. It provides us with an outstanding opportunity to expeditiously develop lonafarnib for HDV infection,” said Joanne Quan, MD, Chief Medical Officer. “The granting of Fast Track status is an important achievement that can facilitate accelerated review of an NDA submission based on the expected data from our development program with the goal of bringing the first approved treatment to HDV patients as quickly as possible.”

About Lonafarnib
Lonafarnib is a well-characterized, late stage, orally active agent targeting farnesyltransferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cellular process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. Since prenylation is carried out by a host enzyme there is also a theoretical higher barrier to develop viral resistance mutations with lonafarnib therapy.

Lonafarnib has been granted Orphan Drug Designation by the US FDA and the European Medicines Agency (EMA). Lonafarnib is an investigational product and its safety and efficacy have not yet been established for any indication.

About HDV
Hepatitis Delta is caused by infection with the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans. Hepatitis D occurs only as a co-infection in individuals with hepatitis B (HBV), leads to more severe liver disease than HBV alone, and is associated with accelerated liver fibrosis, liver cancer, and liver failure. HDV is a disease with a significant impact on global health affecting ~15 million people worldwide. The prevalence of HDV varies between different parts of the world. Globally, HDV infection is reported to be 5-6% of chronic hepatitis B carriers. In some parts of the world, including certain areas of China, Russia,Central Asia, Turkey, Africa, and South America, prevalence as high as 40% has been reported in HBV infected patients.

About Eiger
Eiger is a privately held biotechnology company focused on the research, development and commercialization of innovative therapies for orphan diseases. The company’s lead program is focused on developing lonafarnib for the treatment of hepatitis delta virus (HDV), the most severe form of viral hepatitis. For additional information about Eiger, please visit www.eigerbio.com.

Investors: Jim Shaffer, Eiger BioPharmaceuticals, Inc., 919-345-4256, jshaffer@eigerbio.com

Logo – http://photos.prnewswire.com/prnh/20141221/165715LOGO

Source: Eiger BioPharmaceuticals, Inc.
Related Links:

Written by asiafreshnews

April 21, 2015 at 3:35 pm

Posted in Uncategorized

Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer

leave a comment »

— Animal model highly representative of late-stage ovarian cancer in women
— Model proven resistant to all previous experimental and standard therapies
— Cantrixil providing potent anti-cancer effect

NEW YORK, /PRNewswire/ — US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve the survival outlook for patients with ovarian cancer. The data was presented by Professor Gil Mor ofYale Medical School to the American Association for Cancer Research (AACR) Annual Meeting.

Development of chemo-resistance is a major hurdle in the management of patients with ovarian cancer and this phenomenon is responsible for the high mortality associated with this disease. Growing evidence suggests that chemo-resistance is due to the presence in the tumor of a population of cancer cells with stem cell-like properties that are inherently drug-resistant, surviving radiotherapy and chemotherapy to produce a recurrent cancer re-populated with a new generation of chemo-resistant cancer cells.

There is an urgent need to develop treatments that will kill this population of stem cell-like cancer cells before they have a chance to establish a high degree of chemo-resistance. That is the rationale behind the development of Cantrixil, and the current data suggests that Cantrixil has the potential to be such a breakthrough treatment.

Researchers at the Yale Medical School have established clinically relevant in vitro and in vivo models of chemo-resistant ovarian cancer, providing a tool that drug developers increasingly are accessing to screen prospective drugs against. This is a highly stringent screen that Yale believes provides a rapid go/no-go decision point for lead drug-candidates. To date, no drug candidate has provided a meaningful or durable anti-cancer effect in this model. In this highly aggressive model, intra-peritoneal Cantrixil treatment effectively prevented tumor recurrence by 95%.

In vitro studies have been reported previously. TRXE-002 initially was identified as having potent activity against epithelial ovarian cancer (EOC) stem cells, inducing cell death (apoptosis) in a library of patient-derived EOC stem cells (IC50 of 130 – 250 nM).

To replicate recurrent ovarian cancer in vivo, Yale researchers inject human ovarian cancer stem cells directly into the peritoneal cavity of mice where they develop into a highly aggressive cancer that spreads throughout the abdominal cavity. The appearance and behavior of the cancer mirrors human ovarian cancer primary disease. Once established, the mouse then is treated with the chemotherapy drug, paclitaxel, the standard first-line treatment for ovarian cancer. Following an initial partial response, the tumor quickly regains rapid growth despite ongoing paclitaxel therapy. This produces a late-stage cancer condition (secondary or recurrent disease) that replicates the situation that Cantrixil will encounter initially in the clinic.

In the model of primary disease, Cantrixil administered intraperitoneally as a monotherapy inhibited tumor growth in a dose-dependent manner, significantly reducing terminal tumor burden by >90% (dosage 100 mg/kg; p<0.01) over 17-days of treatment. The treatment was well tolerated with no evidence of bone marrow toxicity or local abdominal toxicity.

More importantly, Cantrixil performed equally well in the far more stringent model of recurrent disease. In this model, following an initial 12-day treatment period with paclitaxel, tumors failed to recur (<95% terminal tumor burden) in those animals switched to daily treatment with intra-peritoneal Cantrixil, compared to animals that remained on treatment with paclitaxel.

Lead Investigator, Gil Mor MD PhD, said, “This animal data shows that it is possible with a drug that targets the chemo-resistant ovarian cancer stem cells to prevent recurrence. Taken together, the data from both the primary and recurrent disease models demonstrate that not only is Cantrixil effective as a first-line monotherapy in a clinically relevant model of ovarian cancer, but more importantly it also prevents tumor recurrence, again in a highly relevant model of drug-resistant and recurrent ovarian cancer,” Mor added.

David Brown PhD, Novogen Group Chief Scientific Officer, said, “Gil Mor’s team have shown that cell death from TRXE-002 is associated with the activation of the pro-death JNK pathway, concurrent with down-regulation of the MAPK pro-survival pathway through prevention of p-ERK signaling. As a molecular biologist, this is a particularly exciting discovery because this novel dual effect on cell-death and cell-survival pathways is believed to explain why TRXE-002 is such an efficient killer of both ovarian cancer cells and the highly chemo-resistant ovarian cancer stem cells, and opens up the opportunity for an entirely new class of chemotherapy.”

Graham Kelly, Novogen Group Chief Executive Officer, said, “It is easy to downplay the importance of pre-clinical data. But the significance of this data needs to be seen in the perspective of the high failure rate of anti-cancer drugs that enter the clinic. For every 50 experimental anti-cancer drugs that enter the clinic, only 1 or 2 ever make it to market. There are a multitude of reasons for this appallingly high attrition rate, but one of the main ones is the lack of relevance of the animal model that was used to justify bringing it into patients in the first place.

“The animal models developed by Yale bring an entirely new level of stringency to the quest for finding an effective treatment for both primary and recurrent ovarian cancer. The performance of Cantrixil in a model that arguably is the most representative of human ovarian cancer yet developed gives us reason to be confident about the potential of this agent as a new form of chemotherapy for this significant unmet clinical need.”

About Ovarian Cancer

Approximately 1 in 70 women will develop ovarian cancer in their lifetime. In the US this equates each year to approximately 22,000 new cases diagnosed and 15,000 deaths from ovarian cancer; the figures for Europe are 66,000 and 41,000 respectively. There are different forms of ovarian cancer with epithelial ovarian cancer accounting for 90% of cases.

Approximately 15% of women present with disease localized to the ovaries and with successful surgery the 5-year survival rate is >90%.

For women with more advanced disease at the time of diagnosis, the 5-year survival rate is <30%.

Approximately 85% of advanced cases respond to first-line therapy (typically paclitaxel and carboplatin), but 80% of these will relapse within several years.

About Cantrixil

Cantrixil is a cyclodextrin envelope containing the active ingredient, TRXE-002. The construct has been designed as an intra-cavity chemotherapy to be injected directly into the peritoneal and pleural cavities without causing local irritation or toxicity. Its purpose is to achieve high drug levels in the environment in which the cancer is spreading through the migration of the cancer stem cells are spreading. The ultimate primary indication of Cantrixil to be sought is first-line therapy of early-stage cancers of the abdominal cavity (e.g. ovarian, uterine, colo-rectal and gastric carcinomas). Cantrixil will enter the clinic in later-stage cancers where the abdominal carcinomatosis has resulted in the terminal condition of malignant ascites.

Cantrixil is owned by CanTx, Inc.

About TRXE-002

TRXE-002 is a small molecule cytotoxic belonging to a family of compounds whose anti-cancer function is based on various biological effects including inhibition of trans-membrane electron-transfer mechanisms. TRXE-002 is pan anti-cancer acting, resulting in caspase-dependent apoptosis of both stem cell-like cancer cells and their daughter cancer cells. The compound has a high therapeutic index with little cytotoxic effect on non-tumor cells.

About CanTx, Inc

CanTx is a joint venture company between Novogen and Yale University. Novogen has licensed the drug candidate, TRXE-002, to CanTx for use in Cantrixil. CanTx is based in New Haven, CT.

About Novogen Limited

Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.

The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).

Further information is available on our website www.novogen.com.

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com 

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,”  “may,” “target,”  “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, Cantrixil and TRXE-002, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to Cantrixil and TRXE-002, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, Cantrixil and TRXE-002, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil and TRXE-002, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Source: Novogen Ltd
Related Links:

Written by asiafreshnews

April 21, 2015 at 2:40 pm

Posted in Uncategorized

Greener Meetings in Asia Pacific with Hilton Worldwide’s Clean Air Program

leave a comment »

SINGAPORE /PRNewswire/ — Hilton Worldwide today announced that it will reduce the environmental impact of meetings and events held at more than 90 hotels and resorts in Asia Pacific through an expanded carbon emissions solution, the Clean Air Program. Starting on May 1, meeting planners and delegates can play their part in reducing carbon emissions and deliver more sustainable experiences to their customers.

When customers choose any of Hilton’s participating hotels as meeting venues, the Clean Air Program will provide a calculation of the carbon emissions of the event at no cost to the customers. Hilton will then purchase the equivalent carbon credits to finance environmentally-friendly projects across Asia Pacific in partnership with carbon offset solutions provider Climate Friendly. The program is designed to make it easier for meeting professionals to incorporate environmental solutions into meetings and events.

Martin Rinck, president, Asia Pacific, Hilton Worldwide said, “Managing our environmental impact and developing new products to enhance the customer experience are  part and parcel of how we operate as a business. Apart from consistently seeking opportunities to reduce waste and conserve energy in our daily operations, the Clean Air Program allows us to take our commitment to sustainability one step further. By offsetting carbon emissions from meetings and events, it means that we can provide essential financing to renewable energy, forest protection and restoration projects which is critical in mitigating climate change.”

Increasingly, investors and consumers worldwide have a greater appreciation of the need for sustainable development, and many leading companies around the world are incorporating sustainable practices into their business models1. Underscored by Hilton’s corporate responsibility strategy, Travel with Purpose, the Clean Air Program was designed as a valued opportunity for both Hilton and its customers to share a commitment to host more eco-friendly meetings. The Clean Air Program is an evolution of the Carbon Offset Program which was previously offered in more than 30 properties in Australasia, Southeast Asia and Japan.

Dominic Sherry, head of sales, Asia Pacific, Hilton Worldwide said, “Today’s customers seek greater meaning in their event experiences and would like event planners to consider the broader implications of the meeting itself. Offering the Clean Air Program at our participating hotels and resorts incorporates a tangible, yet hassle-free solution that delivers on the corporate responsibility commitments of our customers and Hilton.”

The Clean Air Program covers all events such as meetings, conferences, weddings and other social occasions held in participating hotels and resorts. Hilton will use LightStay, its proprietary system developed to calculate and analyze environmental performance, to track and measure carbon emissions from every meeting and event. Its “meeting calculator” feature takes into account the function room’s water and electricity usage, and the food consumed at the event.

Hilton has identified nine projects across Asia Pacific to be funded under the Clean Air Program. These projects, located in countries where Hilton operates, prevent greenhouse gases by producing renewable energy or preserving forests.

For more information on the Clean Air Program and selected projects, please visit:www.HiltonWorldwideMeetingsAPAC.com/CleanAir.

About Climate Friendly
Climate Friendly is a trusted advisor and experienced partner to companies around the world wanting to build and increase business value. We help organizations save energy, reduce costs and build broader commercial value while addressing environmental and social impacts.

Visit www.climatefriendly.com for more information.

About Travel with Purpose
Travel with Purpose is Hilton Worldwide’s commitment to provide shared value to its business and communities around the world. As the driving strategy for Hilton Worldwide’s corporate responsibility efforts, Travel with Purpose focuses on creating opportunities for individuals to reach their full potential; strengthening local communities where Team Members live, work and travel; celebrating cultures and the power of travel; and living sustainably through the measurement, analysis and improvement of the use of natural resources. Visitcr.hiltonworldwide.com for more information.

About Hilton Worldwide
Hilton Worldwide (NYSE: HLT) is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 95 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company’s portfolio of twelve world-class global brands is comprised of more than 4,300 managed, franchised, owned and leased hotels and timeshare properties, with more than 715,000 rooms in 94 countries and territories, including Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio – A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonors®. Visit news.hiltonworldwide.com for more information and connect with Hilton Worldwide at www.facebook.com/hiltonworldwide,www.twitter.com/hiltonworldwide, www.youtube.com/hiltonworldwide, www.flickr.com/hiltonworldwide, andwww.linkedin.com/company/hilton-worldwide.

CONTACT:
Joyce Moo
Hilton Worldwide
+65 6833 9703
joyce.moo@hilton.com

1 Channel NewsAsia Sustainability Rankings – http://sustainability-ranking.channelnewsasia.com/about.html and  PwC Investor Resource Institute’s Survey Findings – http://www.pwc.com/us/en/press-releases/2014/pwc-survey-finds-majority-of-investors-consider-sustainability-issues.jhtml

Source: Hilton Worldwide

Related stocks: NYSE:HLT

Written by asiafreshnews

April 21, 2015 at 12:59 pm

Posted in Uncategorized

Internet of Things Will Deliver US$1.9 Trillion Boost to Supply Chain and Logistics Operations

leave a comment »

-DHL and Cisco Internet of Things Trend Report reveals huge potential for more efficient and transparent supply chains
-An estimated US$8 trillion to be generated through new connections over next decade

SINGAPORE  /PRNewswire/ — DHL, the world’s leading logistics service provider, and Cisco, the worldwide leader in IT, have jointly released a new Trend Report focused on the Internet of Things (IoT) at the DHL Global Technology Conference in Dubai. DHL and Cisco Consulting Services are also collaborating on a joint IoT innovation project that will improve decision-making in warehouse operations with near real-time data analytics based on Wi-Fi connected devices.

Ken Allen, CEO DHL Express and Board Sponsor Technology, said: “At Deutsche Post DHL Group we have a deeply held belief in the positive powers of global trade. Yet, as our Global Connectedness Index[1] 2014 revealed, the overall level of global connectedness remains surprisingly limited. There is huge potential for countries to further increase their connectedness and prosper through trade, integration and technology. We believe the Internet of Things will be a primary enabler of this global transformation.”

The Trend Report, which estimates that there will be 50 billion devices connected to the Internet by 2020 compared to 15 billion today, looks at the potential impact this technological revolution will have on business. The value at stake, combination of increased revenues and lower costs that is created or will migrate among companies and industries when new connections are made, reveals the huge potential when the Internet and networks expand their connections to warehousing, freight transportation and other elements of the supply chain. For any organization with a supply chain or logistics operations, IoT will have game-changing consequences, from creating more ‘last mile’ delivery options for customers, to more efficient warehousing operations and freight transportation.

According to Cisco’s economic analysis, IoT will generate US$8 trillion worldwide in Value at Stake over the next decade. This will come from five primary drivers: innovation and revenue (US$2.1 trillion); asset utilization (US$2.1 trillion); supply chain and logistics (US$1.9 trillion); employee productivity improvements (US$1.2 trillion); and enhanced customer and citizen experience (US$700 billion).

“Digital disruption is all around us and it’s having massive implications for business. Digitization and the expansion of the Internet of Things is a catalyst for growth, which is driving new economic models and enabling organizations to remain competitive and embrace the pace of change happening globally. This report clearly demonstrates that digitization and the IoT will deliver long term efficiencies and growth opportunities across a wide range of industries,” commented Chris Dedicoat, president, EMEAR for Cisco.

According to the report, over the next decade, the logistics industry could unlock higher levels of operational efficiency as the IoT connects in real time millions of shipments being moved, tracked and stowed each day. In warehousing, connected pallets and items will be a driver for smarter inventory management. In freight transportation, tracking and tracing of goods becomes faster, more accurate, predictive and secure while analytics of a connected fleet can help to predict asset failure and to schedule maintenance checks automatically. Finally, connecting delivery personnel with surrounding vehicles and people can become a way of monetizing and optimizing the return trip to improve efficiency and service in last mile delivery. For customers, this means DHL can provide an even faster, more reliable and cost-effective service.

“The Internet of Things is the connection of almost anything  from parcels to people  via sensor technology to the web and both Cisco and DHL believe this will revolutionize business processes across the entire value chain including supply chain and logistics. To get the maximum global economic benefit, we’ll need to understand how all components in the value chain converge and this will require a comprehensive collaboration, participation and the willingness to invest to create a thriving IoT eco system for sustainable business processes. The new Trend Report is another step towards making sure DHL delivers the benefits of IoT to our customers” said Markus Kückelhaus, Vice President Innovation & Trend Research, DHL Customer Solutions & Innovation.

Cisco Consulting Services and DHL are now also collaborating on a joint IoT innovation project that will improve decision-making in the warehouse operations through near real-time data analytics based on Wi-Fi location data of selected devices. The solution is based on Cisco’s Connected Mobile Experiences (CMX) which uses the high-density wireless network to collect aggregate location data on Wi-Fi connected devices.

[1] A detailed analysis of the state of globalization around the world showing global connectedness, measured by cross-border flows of trade, capital, information and people.

— End —

The Trend Report “Internet of Things in Logistics” is available online at www.dhl.com/internetofthings

You can find the press release for download as well as further information on http://www.dpdhl.com/pressreleases

DHL — The logistics company for the world

DHL is the leading global brand in the logistics industry. DHL’s family of divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, international express, road, air and ocean transport to industrial supply chain management. With about 325,000 employees in over 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global trade flows. With specialized solutions for growth markets and industries including e-commerce, technology, life sciences and healthcare, energy, automotive and retail, a proven commitment to corporate responsibility and an unrivalled presence in developing markets, DHL is decisively positioned as “The logistics company for the world.

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 56 billion euros in 2014.

About Cisco

Cisco (NASDAQ: CSCO) is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. For ongoing news, please go to http://thenetwork.cisco.com.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco’s trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

On the Internet: www.dpdhl.de/press
Follow us at: www.twitter.com/DeutschePostDHL
Cisco Internet of Everything: www.cisco.com/go/ioe
Cisco Connected Transportation: www.cisco.com/go/transportation
Twitter: @Cisco

Logo – http://www.prnasia.com/sa/2010/09/02/20100902467742-l.jpg

Source: DHL

Related stocks: NASDAQ-NMS:CSCO

Written by asiafreshnews

April 21, 2015 at 12:58 pm

Posted in Uncategorized